Page last updated: 2024-11-01

ofloxacin and Gastritis

ofloxacin has been researched along with Gastritis in 11 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Gastritis: Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.

Research Excerpts

ExcerptRelevanceReference
" Two groups exhibited similar adverse event rates (AEA 14."3.11Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China. ( He, XJ; Jiang, CS; Li, DZ; Liu, G; Wang, W; Zeng, XP, 2022)
" dosing of levofloxacin (81%[95% CI: 78%-89%]vs 84%[95% CI: 66%-97%])."2.43Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. ( Chey, WD; Kim, HM; Saad, RJ; Schoenfeld, P, 2006)
"Acute phlegmonous gastritis is an uncommon disease, often fatal condition characterized by suppurative bacterial infection of the gastric wall."1.37[A case of acute phlegmonous gastritis causing gastroparesis and cured with medical treatment alone]. ( Kim, JS; Kim, NY; Lee, KJ; Park, JS; Yun, HK, 2011)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19901 (9.09)18.7374
1990's1 (9.09)18.2507
2000's5 (45.45)29.6817
2010's3 (27.27)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
He, XJ1
Zeng, XP1
Jiang, CS1
Liu, G1
Li, DZ1
Wang, W1
Ishigami, T1
Fujikawa, H1
Miyagawa, M1
Arakawa, Y1
Abe, H1
Ryuzaki, H1
Matsuoka, S1
Moriyama, M1
Li, Y1
Huang, X1
Yao, L1
Shi, R1
Zhang, G1
Zhang, J1
Ye, LP1
Li, W1
Shen, LY1
Kim, NY1
Park, JS1
Lee, KJ1
Yun, HK1
Kim, JS1
Saad, RJ1
Schoenfeld, P1
Kim, HM1
Chey, WD1
Vakil, N1
Nista, EC1
Candelli, M1
Zocco, MA1
Cremonini, F1
Ojetti, V1
Finizio, R1
Spada, C1
Cammarota, G1
Gasbarrini, G1
Gasbarrini, A1
Zullo, A1
Hassan, C1
Lorenzetti, R1
Morini, S1
Zelenková, J1
Toman, R1
Bielaszewská, M1
Hanika, J1
Zeman, V1
Glupczynski, Y1
Labbe, M1
Burette, A1
Delmee, M1
Avesani, V1
Bruck, C1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157]102 participants (Actual)Interventional2015-02-28Completed
Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012]51 participants (Actual)Interventional2013-11-30Completed
Personalized Treatment for Refractory H Pylori Infection[NCT02547025]126 participants (Actual)Interventional2012-08-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants in Which H. Pylori Was Eradicated

Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.

Interventionparticipants (Number)
Esomeprazole+Amox+Levo36
Esomeprazole+Bismuth+Tetra+Levo49

Number of Participants in Which H. Pylori Was Eradicated

Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.

Interventionparticipants (Number)
Esomeprazole+Amox+Levo+Tetra13
Esomeprazole+Amox+Levo21

Reviews

2 reviews available for ofloxacin and Gastritis

ArticleYear
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
    Wiener klinische Wochenschrift, 2010, Volume: 122, Issue:13-14

    Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Re

2010
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast

2006
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast

2006
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast

2006
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast

2006
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast

2006
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast

2006
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast

2006
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast

2006
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast

2006

Trials

3 trials available for ofloxacin and Gastritis

ArticleYear
Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China.
    Digestive diseases and sciences, 2022, Volume: 67, Issue:1

    Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; China; Drug Therapy, Combination; Esomepraz

2022
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:9

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; E

2006
Treatment failure of ofloxacin in Campylobacter pylori infection.
    Lancet (London, England), 1987, May-09, Volume: 1, Issue:8541

    Topics: Anti-Bacterial Agents; Campylobacter; Campylobacter Infections; Clinical Trials as Topic; Double-Bli

1987

Other Studies

6 other studies available for ofloxacin and Gastritis

ArticleYear
[A case of phlegmonous gastritis which resolved with medical treatment].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2008, Volume: 105, Issue:7

    Topics: Aged; Anti-Bacterial Agents; Cellulitis; Drug Therapy, Combination; Female; Gastritis; Humans; Levof

2008
Iatrogenic gastric wall abscess infected with Enterobacter cloacae after biopsy.
    Gastrointestinal endoscopy, 2010, Volume: 72, Issue:6

    Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Diagnosis, Differential; Drug Therapy, Comb

2010
[A case of acute phlegmonous gastritis causing gastroparesis and cured with medical treatment alone].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, May-25, Volume: 57, Issue:5

    Topics: Acinetobacter; Acute Disease; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Ceftri

2011
Helicobacter pylori treatment: a practical approach.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination;

2006
Helicobacter pylori eradication: do we have another ace up our sleeve?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2001, Volume: 33, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Infective Agents; Be

2001
[Campylobacter pylori and treatment of duodenal ulcer].
    Vnitrni lekarstvi, 1990, Volume: 36, Issue:6

    Topics: Adult; Campylobacter; Campylobacter Infections; Duodenal Ulcer; Female; Gastritis; Humans; Male; Mid

1990